elastase/inflammation

BACKGROUND ART Elastase is a general term that describes a group of protease enzymes that have the ability to degrade elastin. Elastin is the primary extracellular matrix protein that confers elastic qualities to a variety of tissues including the lung, skin and blood vessels. Different proteases

BACKGROUND OF THE INVENTION We have found that tetrazolyl derivatives of .beta.-lactams such as cephalosporins and penicillins are potent elastase inhibitors and therefore useful anti-inflammatory/antidegenerative agents. Proteases from granulocytes and macrophages have been reported to be

BACKGROUND OF THE INVENTION We have found that tetrazolyl derivatives of .beta.-lactams such as cephalosporins and penicillins are anti-inflammatory/antidegenerative agents. potent elastase inhibitors and therefore useful Proteases from granulocytes and macrophages have been reported to be

BACKGROUND OF THE INVENTION We have found that a group of new substituted azetidinones are potent elastase inhibitors and therefore are useful anti-inflammatory and antidegenerative agents. Proteases from granulocytes and macrophages have been reported to be responsible for the chronic tissue

BACKGROUND OF THE INVENTION We have found that a group of new substituted azetidinones are potent elastase inhibitors and therefore are useful anti-inflammatory and antidegenerative agents. Proteases from granulocytes and macrophages have been reported to be responsible for the chronic tissue

This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 ##STR00002## and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary,

This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 ##STR00002## and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary,

This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 ##STR00002## and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary,

FIELD OF THE INVENTION This invention relates to substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and

FIELD OF THE INVENTION This invention relates to substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and

FIELD OF THE INVENTION This invention relates to substituted 2-pyridones and pyrazinones of formula 1 ##STR00002## and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of

This application is the U.S. national stage entry under 35 U.S.C. 371 of PCT/FR95/00768, filed Jun. 12, 1995. The present invention concerns a novel use of sophorolipids. The present invention also concerns cosmetic or dermatological compositions. More particularly, the present invention concerns

BACKGROUND OF THE INVENTION We have found that sulfones of substituted cephalosporins are potent elastase inhibitors and therefore are useful anti-inflammatory/antidegenerative agents. Proteases from granulocytes and macrophages have been reported to be responsible for the chronic tissue destruction

BACKGROUND OF THE INVENTION We have found that sulfoxides of substituted cephalosporins are potent elastase inhibitors and therefore are useful anti-inflammatory/antidegenerative agents. Proteases from granulocytes and macrophages have been reported to be responsible for the chronic tissue

BACKGROUND OF THE INVENTION We have found that a group of new substituted azetidinones are potent elastase inhibitors and therefore are useful anti-inflammatory/antidegenerative agents. Proteases from granulocytes and macrophages have been reported to be responsible for the chronic tissue